Validation of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ v. 2.1) for patients undergoing prophylactic migraine treatment
- PMID: 17468941
- DOI: 10.1007/s11136-007-9217-1
Validation of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ v. 2.1) for patients undergoing prophylactic migraine treatment
Abstract
Objective: Health-related quality of life (HRQoL) is an important outcome measure of migraine treatments. Although a number of migraine-specific HRQoL questionnaires exist, their measurement characteristics have only been examined for patients undergoing acute treatment of migraine. The goal of the current study was to evaluate measurement properties of the widely used Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ v. 2.1) within a group of patients undergoing prophylactic migraine treatment.
Methods: Various measurement properties of the MSQ were examined in a sample of 916 migraineurs undergoing prophylactic treatment who had scores at baseline and follow-up, as well as baseline SF-36. First, we used confirmatory factor analysis (CFA) and differential item functioning (DIF) to assure the accuracy and stability across groups of the MSQ scoring for all three subscales (Role Restrictive, Role Preventive, and Emotional Functioning). Next, item- and scale-level properties were examined, such as item-total correlations, internal consistency, and convergent and discriminant validity.
Results: Initial findings revealed that item 12 (measuring frustration on the Emotional Functioning subscale) performed poorly. Subsequent to its removal, the 13-item MSQ displayed excellent measurement properties, including stable latent structure at baseline and endpoint, no gender or age biases on items, appropriate item-level and scale-level reliabilities, and markedly higher convergent validity compared to discriminant validity.
Conclusion: The 13-item MSQ appears to be an appropriate measure of migraine-specific HRQoL for patients undergoing migraine prophylaxis. Moreover, given the stability of the latent structure over time, the interpretation of scores is likely to remain quite consistent throughout a clinical trial.
Similar articles
-
The psychometric properties of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ) in chronic migraine patients.Qual Life Res. 2013 Jun;22(5):1123-33. doi: 10.1007/s11136-012-0230-7. Epub 2012 Jul 15. Qual Life Res. 2013. PMID: 22797868 Free PMC article.
-
Identifying patients who require a change in their current acute migraine treatment: the Migraine Assessment of Current Therapy (Migraine-ACT) questionnaire.Curr Med Res Opin. 2004 Jul;20(7):1125-35. doi: 10.1185/030079904125004079. Curr Med Res Opin. 2004. PMID: 15265257
-
Validating Migraine-Specific Quality of Life Questionnaire v2.1 in episodic and chronic migraine.Headache. 2012 Mar;52(3):409-21. doi: 10.1111/j.1526-4610.2011.01997.x. Epub 2011 Sep 19. Headache. 2012. PMID: 21929662
-
Evolution of the measurement of quality of life in migraine.Neurology. 1997 Mar;48(3 Suppl 3):S10-5. doi: 10.1212/wnl.48.3_suppl_3.10s. Neurology. 1997. PMID: 9071264 Review.
-
[Influence of treatments for migraine on quality of life: literature integrative review].Rev Bras Enferm. 2012 Mar-Apr;65(2):353-60. doi: 10.1590/s0034-71672012000200023. Rev Bras Enferm. 2012. PMID: 22911421 Review. Portuguese.
Cited by
-
Evaluation of the effect of erenumab on migraine-specific questionnaire in patients with chronic and episodic migraine.CPT Pharmacometrics Syst Pharmacol. 2023 Dec;12(12):1988-2000. doi: 10.1002/psp4.13048. Epub 2023 Oct 11. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 37723849 Free PMC article.
-
Tai Chi for the prophylaxis of episodic migraine: protocol of a non-inferiority randomized controlled trial with mechanism exploration.BMC Complement Med Ther. 2023 Sep 18;23(1):328. doi: 10.1186/s12906-023-04154-x. BMC Complement Med Ther. 2023. PMID: 37723467 Free PMC article.
-
Periaqueductal gray matter echogenicity as a marker of migraine chronification: a case control study.J Headache Pain. 2023 Apr 17;24(1):41. doi: 10.1186/s10194-023-01576-3. J Headache Pain. 2023. PMID: 37069501 Free PMC article.
-
Validation and meaningful within-patient change in work productivity and activity impairment questionnaire (WPAI) for episodic or chronic migraine.J Patient Rep Outcomes. 2023 Apr 4;7(1):34. doi: 10.1186/s41687-023-00552-4. J Patient Rep Outcomes. 2023. PMID: 37016181 Free PMC article. Clinical Trial.
-
L-arginine and aged garlic extract for the prevention of migraine: a study protocol for a randomised, double-blind, placebo-controlled, phase-II trial (LARGE trial).BMC Neurol. 2023 Mar 27;23(1):122. doi: 10.1186/s12883-023-03149-y. BMC Neurol. 2023. PMID: 36973718 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
